Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 274

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 274
---
 failure to vote by proxy or
to vote virtually at the Special Meeting, as well as an abstention from voting or broker non-vote, will have no effect on the outcome
of the Business Combination Proposal.

| 140 |

<div align='center'>PROPOSAL NO. 2 — THE CHARTER APPROVAL PROPOSAL</div>

Overview

The FutureTech
stockholders are also being asked to adopt the Second Amended and Restated Certificate of Incorporation in the form attached hereto as
Annex B, which, in the judgment of our Board, will address the needs of the post-combination company.

The following
is a summary of the key changes effected by the Second Amended and Restated Certificate of Incorporation, but this summary is qualified
in its entirety by reference to the full text of the Second Amended and Restated Certificate of Incorporation, a copy of which is included
as Annex B:

● Change
the post-combination company’s name to Longevity Biomedical, Inc.;

● Provide
that the purpose of the post-combination company to “any lawful act or activity for which corporations may be organized under the
General Corporation Law of the State of Delaware” and delete a prior provision in Article II pertaining to a blank-check company;

● Provide
for a single class of common stock of the post-combination company, entitled to one vote for each share of common stock held of record
by such holder on all matters on which stockholders generally are entitled to vote (other than certain amendments relating to preferred
stock);

● Provide
that the post-combination Board shall consist of seven directors, six of whom shall be nominated by Longevity and one of whom shall be
nominated by our Sponsor, and four of whom shall qualify as an independent director under the rules of The Nasdaq Stock Market (an “Independent
Director”). The directors shall be split among three classes of directors, with the terms of the Class I directors expiring at our
annual meeting of stockholders for 2026, the terms of the Class II directors expiring at our annual meeting of stockholders for 2027,
and the terms of the Class III directors expiring at our annual meeting of stockholders for 2028. At each annual meeting of stockholders,
directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding
annual meeting of stockholders after their election. Such directors shall serve until